Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Talent Acquisition and Retention
  • United States
Search

Webinars

Unlock the Potential of Generative AI in Life Sciences Insights and Operations

May 2, 2024 | 1:00 - 1:45 PM ET

Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. GenAI has the potential to make pharma professionals far more effective and valuable to their organizations. Join us for “Making AI Real,” a webinar series dedicated to exploring how to leverage generative AI across different areas within pharmaceutical commercial operations and medical affairs.

Sign Up Now

Webinars

COVID-19 Forecasting: Seeking Clarity in a World of Uncertainty

Available On Demand

Forecasters in the life sciences industry are facing novel challenges in the midst of the COVID-19 pandemic. With so much at stake, and so much change, forecasting in this environment is both vital and difficult. Companies are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Key Takeaways Insights into assumptions that are critical to projecting the future of the COVID-19 pandemic. Examples of how different scenarios…

Watch Now

Blog

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

Published September 22, 2020

Executive Summary Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…

Read Now

Case Studies

Early Payer Guidance Across Four Inflammatory Disease Areas

Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas. Geographic Scope: Client Situation The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making. Trinity’s Solution Trinity conducted comprehensive secondary research in the following areas: Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…

Read Now

Case Studies

P&MA Assessment to Support BD&L Decision-Making

Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making. Geographic Scope: Client Situation The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making. Trinity’s Solution Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.…

Read Now

Case Studies

Cross-Functional Launch Strategy Alignment Workshop

Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan. Geographic Scope: Client Situation: The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks. Trinity’s Solution: Trinity conducted targeted secondary research to determine the existing mNSCLC…

Read Now

Case Studies

Biosimilar Differentiation Strategy

Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries. Geographic Scope: Client Situation: The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars. Trinity’s Solution Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses,…

Read Now

Case Studies

Strategic Recommendations About Potential Actions to Shape Bone Health Policy

Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets. Geographic Scope: Client Situation The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy. Trinity’s Solution Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space. Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.